- Home
- ALTO vs CRBP Comparison
ALTO vs CRBP Comparison
Compare ALTO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALTO | CRBP |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 202.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ALTO | CRBP |
|---|---|---|
| Price | $2.54 | $9.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $5.50 | ★ $50.29 |
| AVG Volume (30 Days) | ★ 1.5M | 513.0K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $922,309,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.07 | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $4.64 |
| 52 Week High | $2.92 | $20.56 |
Technical Indicators
Market Signals| Indicator | ALTO | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 62.94 | 34.73 |
| Support Level | $2.28 | $9.44 |
| Resistance Level | $2.64 | $11.64 |
| Average True Range (ATR) | 0.25 | 0.74 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 54.17 | 12.16 |
Price Performance
Historical ComparisonAbout ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under four segments: Marketing and distribution, Pekin Campus production, Western production, and Corporate.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.